From the Editor-in-Chief

Paying attention to the social determinants of health will promote greater equity in cancer outcomes for all.

by William G. Nelson, MD, PhD

Forward Look

The Clinical Treatment Act aims to include more Medicaid recipients.

by Jen Tota McGivney

Survivor Profile

Medha Deoras-Sutliff's experience with breast cancer fueled her interest in advocacy for breast cancer patients and, more recently, her support for research on rare cancers.

by Lindsey Konkel

Despite national guidelines urging oncologists to bring up risks of infertility posed by cancer treatment, many young cancer patients are never told about these risks or counseled on their fertility preservation options.

by Marcus A. Banks

Doctors and researchers met online to discuss how the coronavirus pandemic changed cancer care in its early months, as well as how they can improve care and advocate for patients going forward.

by Kate Yandell

What happens if your workplace reopens before you're ready to return or you're an essential worker? For some people who have been diagnosed with cancer, accommodations may be possible.

by Jen Tota McGivney

From the Editor-in-Chief

Surrogate endpoints can speed up drug approvals, but are they valid measures of effectiveness?

by William G. Nelson, MD, PhD

Forward Look

As patents expire on biologic drugs, cancer patients get new options.

by Stephen Ornes

Policy Matters

The AACR and the FDA presented joint recommendations that include broadening clinical trial eligibility and engaging the community in clinical trial recruitment.

by Kenneth C. Anderson, MD; Lola A. Fashoyin-Aje, MD, MPH; Nicole Gormley, MD; and Paul G. Kluetz, MD

Q&A

In her first book, journalist and breast cancer survivor Kate Pickert traces the winding road of cancer research and patient advocacy.

by Marci A. Landsmann